510(k) K231306
K231306 is an FDA 510(k) premarket notification submitted by Roche Molecular Systems, Inc. for the device "cobas SARS-CoV-2 Qualitative for use on the cobas 5800/6800/8800 Systems". The FDA issued a decision of Substantially Equivalent on Jun 1, 2023. The device falls under product code QQX (Respiratory Specimen Nucleic Acid Sars-Cov-2 Test), a Class II device regulated under 21 CFR 866.3981. Roche Molecular Systems, Inc. has 54 other 510(k) clearances on record.
Clearance details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- Jun 1, 2023
- Date Received
- May 5, 2023
- Clearance Type
- Special
- Expedited Review
- No
- Third Party Review
- No
Device classification
- Device Name
- Respiratory Specimen Nucleic Acid Sars-Cov-2 Test
- Device Class
- Class II
- Regulation Number
- 866.3981
- Review Panel
- MI
- Submission Type
- 510(k)
A device to detect and identify nucleic acid targets in respiratory specimens from SARS-CoV-2 that cause COVID-19 is an in vitro diagnostic device intended for the detection and identification of SARS-CoV-2 nucleic acid targets in human clinical respiratory specimens from patients suspected of COVID-19 based on signs and symptoms of respiratory infections by their healthcare providers. The device is intended to aid in the diagnosis of COVID-19 in conjunction with other clinical, epidemiologic, and laboratory data or other risk factors.
Need the full FDA record for Roche Molecular Systems, Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.